Want to see PBLS full AI Analyst Report?
Top Page
Parabilis Medicines, Inc.
(NASDAQ:PBLS)
Select Model
Select Model
Rating:48Neutral
Price Target:
$37.00
▲(3.99% Upside)
Action:N/A
Date:08/18/26
The score is held down primarily by weak financial performance (pre-revenue, widening losses, increasing cash burn, and negative equity), implying high dependence on external funding. Technical indicators provide a partial offset with moderately positive momentum, while valuation is constrained by negative earnings and no dividend yield data.
Positive Factors
Pipeline advancement
Progressing zolucatetide toward registrational development could create a path to future commercialization and diversify the company beyond discovery-stage research if clinical and regulatory milestones are achieved.
Negative Factors
Minimal commercial revenue
The absence of a meaningful revenue base leaves the company dependent on clinical progress and capital markets rather than operating sales, increasing execution risk before any product commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Pipeline advancement
Progressing zolucatetide toward registrational development could create a path to future commercialization and diversify the company beyond discovery-stage research if clinical and regulatory milestones are achieved.
Read all positive factors
Parabilis Medicines, Inc. (PBLS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.75B
Dividend YieldN/A
Average Volume (3M)N/A
Price to Earnings (P/E)―
Beta (1Y)-0.62
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees145
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding121,952,030
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-2.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.33
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue0.02
Enterprise Value/Gross Profit0.02
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$40.67Price Target Upside14.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Parabilis Medicines, Inc. Business Overview & Revenue Model
Company Description
Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The c...
How the Company Makes Money
null...
Parabilis Medicines, Inc. Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
22
Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 148.00K | 0.00 | 0.00 |
| Gross Profit | 148.00K | 0.00 | 0.00 |
| EBITDA | -96.08M | -141.87M | -114.33M |
| Net Income | -97.78M | -145.89M | -117.91M |
Balance Sheet | |||
| Total Assets | 1.18B | 80.82M | 149.25M |
| Cash, Cash Equivalents and Short-Term Investments | 1.12B | 27.71M | 87.98M |
| Total Debt | 47.51M | 58.70M | 66.20M |
| Total Liabilities | 127.53M | 97.34M | 92.81M |
| Stockholders Equity | 1.05B | -16.52M | 56.44M |
Cash Flow | |||
| Free Cash Flow | -53.81M | -124.02M | -104.49M |
| Operating Cash Flow | -52.82M | -123.71M | -103.61M |
| Investing Cash Flow | -34.43M | 39.76M | 30.24M |
| Financing Cash Flow | 1.15B | 64.38M | 78.08M |
Parabilis Medicines, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $1.42B | 19.51 | 284.38% | ― | 948.35% | ― | |
61 Neutral | $3.20B | -66.80 | -13.53% | ― | 105.17% | 53.58% | |
55 Neutral | $2.37B | -7.59 | -59.87% | ― | -8.14% | -10.60% | |
54 Neutral | $2.34B | -8.88 | -273.23% | ― | ― | -10.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $4.75B | -1.04 | -15.14% | ― | ― | ― | |
46 Neutral | $419.85M | -1.34 | -135.81% | ― | -94.63% | -39.78% |
* Healthcare Sector Average
PBLS
Parabilis Medicines, Inc.
39.23
7.63
24.15%
EYPT
EyePoint Pharmaceuticals
5.01
-7.03
-58.43%
OCUL
Ocular Therapeutix
10.88
-1.44
-11.69%
MGTX
Meiragtx Holdings
14.92
7.42
98.93%
KOD
Kodiak Sciences
39.46
29.78
307.64%
TARS
Tarsus Pharmaceuticals
71.45
12.60
21.41%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.